EUVIMEDEUVIMED entdecken
Crossref

Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience

Ben Koszegi iD, Anna Wilson iD, Corey Stone iD, Fanny Satgé iD, Timothy L Cowan iD, Dédée F Murrell iD

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Ben Koszegi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St George Hospital, Sydney, NSW,Australia. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: Sun Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our case series findings indicate that tildrakizumab treatment in patients with hidradenitis suppurativa who previously received adalimumab demonstrated an initial improvement in disease activity within the first 6 months. However, this overall trend was not sustained beyond the 6-month mark. Nevertheless, it is noteworthy that patients who underwent long-term follow-up on tildrakizumab experienced ongoing disease activity but showed a reduction in Dermatology Life Quality Index scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaHumansAdalimumabAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsSeverity of Illness IndexTreatment Outcome

Substanzen

AdalimumabtildrakizumabAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Dermatology, St George Hospital, Sydney, NSW,Australia.
  • Faculty of Medicine, University of New South Wales, Sydney, NSW,Australia.

ORCID-Profile: Ben Koszegi, Anna Wilson, Corey Stone, Fanny Satgé, Timothy L Cowan, Dédée F Murrell

Förderung

  • Sun Pharmaceuticals

Zitieren

APA

Koszegi, B., Wilson, A., Stone, C., Satgé, F., Cowan, T. L., & Murrell, D. F. (2023). Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad215

Vancouver

Koszegi B, Wilson A, Stone C, Satgé F, Cowan TL, Murrell DF. Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad215

BibTeX
@article{Koszegi2023,
  author = {Koszegi, Ben and Wilson, Anna and Stone, Corey and Satgé, Fanny and Cowan, Timothy L and Murrell, Dédée F},
  title = {Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad215}
}
Kostenlos starten →